LEIDEN, Netherlands, July 5, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced that it will release its financial results for the second quarter of 2005 on Monday, July 18, 2005 at 14:00 p.m. Central European Time (CET) (8:00 a.m. U.S. Eastern Standard Time).
Thirty minutes later, at 14:30 p.m. CET, Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following toll-free numbers 10 minutes prior to commencement:
866-328-4274 for the U.S.;
0800-358-5261 for the U.K.; and
0800-265-8531 for the Netherlands.
Following a presentation of the results you will be able to ask questions during a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay from 18:00 p.m. CET following the event.
About Crucell
Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The Company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6(R) production technology. The company also licenses its PER.C6(R) technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
Click here for a PDF version of this press release: http://hugin.info/132631/R/1001388/153354.pdf
For further information please contact:
Crucell N.V.
Harry Suykerbuyk, Director Investor Relations
and Corporate Communications Tel.
+31 (0)71 524 8718
h.suykerbuyk@crucell.com
For Crucell N.V. in the USA:
Redington Inc.
Thomas Redington
(212) 926-1733
tredington@redingtoninc.com